Phase 1
Completed N=103
Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)
Source: ClinicalTrials.gov NCT00541229 ↗Enrolled (actual)
103
Serious AEs
0.0%
Results posted
Jul 2009
Primary outcomePrimary: 24-hour Weighted Mean Glucose (WMG) — 169.1; 159.0; 200.9 mg/dL — p=0.004
Summary
A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY 24-hour Weighted Mean Glucose (WMG) |
169.1; 159.0; 200.9 | 0.004 sig |
Eligibility Criteria
Inclusion Criteria
- Patient has Type 2 Diabetes
- Patient is between the ages of 30-65 years
- Patient is not on an antihyperglycemic agent (AHA) (glycosylated hemoglobin [A1C] 7-10% ), or is on oral single AHA or low-dose combination therapy (A1C 6.5-9.5%).
Exclusion Criteria
- Patient has Type 1 Diabetes
- Patient has been treated with sitagliptin, vildagliptin, or other similar drugs or has been treated with exenatide in the past 3 months
- Patient has taken insulin within the past 3 months
Data sourced from ClinicalTrials.gov (NCT00541229). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.